.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD06_GlimepirideAndPioglitazo.GlimepirideAndPioglitazo .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD06_GlimepirideAndPioglitazo.GlimepirideAndPioglitazo| name: | GlimepirideAndPioglitazone |
| ATC code: | A10BD06 | route: | oral |
| n-compartments | 1 |
Glimepiride and pioglitazone (ATC code A10BD06) is a fixed-dose combination oral medication used in the treatment of type 2 diabetes mellitus. Glimepiride is a second-generation sulfonylurea that stimulates insulin secretion from pancreatic beta cells, and pioglitazone is a thiazolidinedione that improves insulin sensitivity in peripheral tissues. The combination is approved and in clinical use for adults with type 2 diabetes to improve glycemic control when diet, exercise, and single-agent therapy are insufficient.
Estimated pharmacokinetic parameters for the fixed-dose combination product based on known single-agent data as there are no published compartmental pharmacokinetic studies reporting both drug models together in the fixed combination in healthy adults or patients with type 2 diabetes.
Kirchheiner, J, et al., & Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical pharmacokinetics 44(12) 1209–1225. DOI:10.2165/00003088-200544120-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16372821
Kadokura, T, et al., & Smulders, R (2014). Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. Clinical pharmacokinetics 53(11) 975–988. DOI:10.1007/s40262-014-0180-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/25316572